CRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider James Kasinger Sells 1,990 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 1,990 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $60.04, for a total transaction of $119,479.60. Following the completion of the transaction, the general counsel directly owned 94,784 shares of the company’s stock, valued at $5,690,831.36. The trade was a 2.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded down $1.91 during mid-day trading on Thursday, hitting $50.44. 2,863,363 shares of the company’s stock traded hands, compared to its average volume of 1,757,269. The company’s 50-day moving average is $54.99 and its two-hundred day moving average is $53.05. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The company has a market capitalization of $4.88 billion, a P/E ratio of -10.60 and a beta of 1.76. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $78.38.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The business had revenue of $10.18 million during the quarter. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -4.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CRSP. UBS Group set a $80.00 target price on CRISPR Therapeutics in a research report on Friday, June 12th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $67.94.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Green Alpha Advisors LLC lifted its stake in shares of CRISPR Therapeutics by 1.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 56,786 shares of the company’s stock worth $3,141,000 after acquiring an additional 982 shares during the last quarter. Farther Finance Advisors LLC increased its stake in CRISPR Therapeutics by 43.6% in the third quarter. Farther Finance Advisors LLC now owns 11,426 shares of the company’s stock worth $632,000 after purchasing an additional 3,470 shares during the period. Congress Asset Management Co. increased its stake in CRISPR Therapeutics by 1.6% in the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock worth $6,153,000 after purchasing an additional 1,777 shares during the period. Versant Capital Management Inc lifted its position in shares of CRISPR Therapeutics by 131.8% during the third quarter. Versant Capital Management Inc now owns 1,078 shares of the company’s stock worth $60,000 after purchasing an additional 613 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of CRISPR Therapeutics during the second quarter worth $585,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.